|Day Low/High||15.19 / 16.06|
|52 Wk Low/High||4.98 / 18.83|
New Drug Application Submission on Track for 4Q17
It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.
First Oral Precision Medicine for Fabry Disease with Broad Label for Fabry Patients with Amenable Genetic Mutations
Apple and its suppliers are dragging the market down.
The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.
Shares of this biotech look ready for further strong gains.
Teligent, FibroGen and Amicus Therapeutics were among the biotech stock movers in premarket trading on July 21.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
Represents World's Second Largest Diagnosed Global Fabry Patient Population
Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.
Top-Line Data on Track for 3Q17
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.